Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of LINC01703 as molecular marker for liver cancer diagnosis

A technology for liver cancer and auxiliary diagnosis, applied in the field of biomedicine, can solve the problems of liver cancer insensitivity and delay the disease, and achieve the effect of improving the survival rate

Inactive Publication Date: 2018-09-28
QIANFOSHAN HOSPITAL OF SHANDONG
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] However, the defect of using serum markers to diagnose liver cancer is insensitivity, and the defect of using other auxiliary examinations to diagnose liver cancer is that it cannot make a diagnosis in the early stage of the disease, delaying the disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of LINC01703 as molecular marker for liver cancer diagnosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] Example 1 Screening of differentially expressed non-long-chain coding RNA

[0052] 1. Materials:

[0053] Surgically resected cancer tissues and paracancerous tissues of 5 patients with primary liver cancer were used as experimental samples. All cancer tissues were pathologically confirmed as liver cancer. All patients with primary liver cancer had not received radiotherapy and chemotherapy before operation, and the clinical data of all cases were complete. All patients signed the informed consent.

[0054] 2. Steps:

[0055] (1) Use TRIzol reagent to extract total RNA from tissue samples, and use RNasey Mini Kit to purify the extracted RNA;

[0056] (2) Use QuickAmp Labeling Kit, One-Color (Agilent p / n 5190-0442) to synthesize and label double-stranded cDNA;

[0057] (3) After the labeled double-stranded cDNA is purified, it is hybridized to the Human 8x60K LncRNA expression array information chip of Arraystar;

[0058] (4) After hybridization and rinsing, scan a...

Embodiment 2

[0062] Example 2 Large sample verification screened out differentially expressed LncRNA

[0063] Based on the results of previous chip sequencing and according to the size of P value, we selected LINC01703 for verification.

[0064] 1. Sample collection

[0065] According to the method of Example 1, 30 liver cancer tissues and 30 corresponding paracancerous tissues were collected.

[0066] 2. Validation at the mRNA level

[0067] Reagents: Reverse transcription kit (DDR037A) was purchased from Treasure Bioengineering (Dalian) Co., Ltd. SYBR Premix Ex Taq for real-time quantitative PCR (polymerase chain reaction) TM (Tli RNaseHPlus) kit was produced by Japan Takara Company.

[0068] 2.1 Extract tissue RNA

[0069] Step is with embodiment 1.

[0070] 2.2 Reverse transcription

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of LINC01703 as a molecular marker for liver cancer diagnosis. Researches of the invention shows that LINC01703 has significant differences in expression in liver cancer tissue and para-carcinoma tissue; it is considered accordingly that LINC01703 may serve as a molecular marker for the diagnosis of liver cancer. Products suitable for early diagnosis of liver cancer can be developed according to the results of the researches above; the products have high detection rate and are suitable for clinical popularization.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to the application of LINC01703 as a molecular marker for diagnosing liver cancer. Background technique [0002] Primary liver cancer (primary carcinoma of liver, hereinafter referred to as liver cancer) is one of the common malignant tumors in my country. According to statistics in the 1990s, the annual mortality rate of liver cancer in my country is 20.37 / 100,000, ranking second in the death sequence of malignant tumors, second only to lung cancer in cities and gastric cancer in rural areas. Due to the clinical application of serum alpha-fetoprotein (AFP) and the advancement of various imaging techniques, especially the use of AFP and ultrasound imaging in the monitoring of high-risk groups of liver cancer, liver cancer can be diagnosed in the subclinical stage without symptoms and signs. Coupled with the maturity of surgical techniques and the development of non-surgical treatment method...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886A61K45/00A61P35/00
CPCC12Q1/6886A61K45/00A61P35/00C12Q2600/118C12Q2600/158C12Q2600/178
Inventor 李刚
Owner QIANFOSHAN HOSPITAL OF SHANDONG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com